Calcium electroporation for recurrent head and neck cancer: A clinical phase I study.

Autor: Plaschke CC; Department of Otorhinolaryngology, Head & Neck Surgery and Audiology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark., Gehl J; Department of Clinical Medicine Copenhagen University Hospital Rigshospitalet Copenhagen Denmark.; Department of Clinical Oncology and Palliative Care, Center for Experimental Drug and Gene Electrotransfer (CEDGE) Zealand University Hospital Roskilde Denmark.; Department of Oncology Herlev and Gentofte Hospital, University of Copenhagen Herlev Denmark., Johannesen HH; Department of Clinical Physiology, Nuclear Medicine & PET, and Cluster for Molecular Imaging Copenhagen University Hospital Rigshospitalet Copenhagen Denmark., Fischer BM; Department of Clinical Medicine Copenhagen University Hospital Rigshospitalet Copenhagen Denmark., Kjaer A; Department of Clinical Medicine Copenhagen University Hospital Rigshospitalet Copenhagen Denmark., Lomholt AF; Department of Otorhinolaryngology, Head & Neck Surgery and Audiology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark., Wessel I; Department of Otorhinolaryngology, Head & Neck Surgery and Audiology Copenhagen University Hospital Rigshospitalet Copenhagen Denmark.
Jazyk: angličtina
Zdroj: Laryngoscope investigative otolaryngology [Laryngoscope Investig Otolaryngol] 2019 Jan 03; Vol. 4 (1), pp. 49-56. Date of Electronic Publication: 2019 Jan 03 (Print Publication: 2019).
DOI: 10.1002/lio2.233
Abstrakt: Background: Calcium electroporation is a novel cancer treatment, which combines temporary cell permeability from electroporation with a high influx of calcium intracellularly resulting in cancer cell necrosis.
Methods: A phase I trial performing calcium electroporation on 6 patients suffering from recurrent head and neck cancer. In general anesthesia, intratumoral calcium injections were followed by electroporation. Safety was monitored by adverse events registration, serum Ca 2+ , ECG, and pain scores. Tumor response was measured on PET/MRI scans.
Results: Procedures were performed without complications. No serious adverse events, signs of hypercalcemia, or cardiac arrhythmias were observed. Two months post-treatment tumor responses on MRI: three partial responses, one stable disease, and two progression. Responses on PET: one partial metabolic disease, four with stable metabolic disease, and one not evaluable. One patient was without clinical evidence of disease after 12 months of observation.
Conclusion: Calcium electroporation is feasible and safe in head and neck tumors. Clinical responses were observed in three of six patients, warranting further studies.
Level of Evidence: Level 4.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje